ClinicalTrials.gg
CompletedNCT03905330MARCH-PFICUpdated Dec 11, 2023Results posted

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

A Phase 3 interventional study of Maralixibat and Placebo in Progressive Familial Intrahepatic Cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc.. Completed at 31 sites in 17 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cholestasis, progressive familial intrahepatic 1 · United States.

Started
2019
the only one that year
Phase 3
3 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
6 of 10
Mirum Pharmaceuticals, Inc.

Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, this one is the only one that started in 2019, is one of 3 in phase 3, and was the 6th registered.

Cholestasis, progressive familial intrahepatic 1

33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.

Browse Cholestasis, progressive familial intrahepatic 1 studies →

Open to participants now

1 of the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Cholestasis, progressive familial intrahepatic 1 studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric participants with Progressive Familial Intrahepatic Cholestasis (PFIC).

Read the detailed description

This study was conducted at multiple sites in North America, Europe, Asia and South America.

03

Conditions studied

  • Progressive Familial Intrahepatic Cholestasis (PFIC)

Keywords

  • Cholestasis
  • Maralixibat
  • Mutation
  • PFIC
  • PFIC2
  • Bile Duct Diseases
  • Liver Diseases
  • Biliary Tract Diseases
  • Digestive System Diseases
  • Pediatric
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. and assent (as applicable) per Institutional Review Board/Ethics Committee (IRB/EC)
  2. Male or female subjects with a body weight ≥5 kg, who are ≥12 months and \<18 years of age at time of baseline
  3. Cholestasis as manifested by total sBA ≥3× (applies to primary cohort only)
  4. An average AM ItchRO(Obs) score ≥1.5 during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1)
  5. Completion of at least 21 valid* morning ItchRO(Obs) entries during 4 consecutive weeks of the screening period, leading to the baseline visit (Visit 1) (*valid = completed and not answered as "I don't know"; maximum allowed invalid reports = 7, no more than 2 invalid reports during the last 7 days before randomization)
  6. Diagnosis of PFIC based on the following:

    • Chronic cholestasis as manifested by persistent (>6 months) pruritus in addition to biochemical abnormalities and/or pathological evidence of progressive liver disease and
    • Primary Cohort: Subjects with genetic testing results consistent with biallelic disease-causing variation in ABCB11 (PFIC2), based on standard of care genotyping
    • Supplemental Cohort: i. Subjects with genetic testing results consistent with biallelic disease-causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or TJP2 (PFIC4), based on standard of care genotyping. ii. Subjects with PFIC phenotype without a known mutation or with another known mutation not described above or with intermittent cholestasis as manifested by fluctuating sBA levels. iii. Subjects with PFIC after internal or external biliary diversion surgery or for whom internal or external biliary diversion surgery was reversed.
  7. Male and females of non-. Males and non-pregnant, non-lactating females of childbearing potential who are sexually active must agree to use acceptable methods of during the study and 30 days following the last dose of the study medication. Females of childbearing potential must have a negative pregnancy test
  8. Access to email or phone for scheduled remote visits
  9. Ability to read and understand the questionnaires (both caregivers and subjects above the age of assent)
  10. Access to consistent caregiver(s) during the study
  11. Subject and caregiver willingness to comply with all study visits and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Predicted complete absence of bile salt excretion pump (BSEP) function based on the type of ABCB11 mutation (PFIC2), as determined by a standard of care genotyping (applies to primary cohort only). Subjects can enter the study in the Supplemental Cohort (under inclusion criteria 6.ii or 6.iii).
  2. Recurrent intrahepatic cholestasis, indicated by a history of sBA levels \<3x or intermittent pruritus (applies to primary cohort only)
  3. Current or recent history (\<1 year) of atopic dermatitis or other non-cholestatic diseases associated with pruritus.
  4. History of surgical disruption of the enterohepatic circulation (applies to primary cohort only)
  5. Chronic diarrhea requiring intravenous fluid or nutritional intervention for the diarrhea and/or its sequelae at screening or during the 6 months prior to screening
  6. Previous or need for imminent liver transplant
  7. Decompensated cirrhosis ( [INR] >1.5, albumin \<30 g/L, history or presence of ascites, variceal hemorrhage, and/or encephalopathy)
  8. or total serum (TSB) >15× ULN at screening
  9. Presence of other liver disease
  10. Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine (e.g., inflammatory bowel disease), per Investigator discretion
  11. Possibly malignant liver mass on imaging, including screening ultrasound
  12. Known diagnosis of (HIV) infection
  13. Any prior cancer diagnosis (except for in situ carcinoma) within 5 years of the screening visit (Visit 0)
  14. Any known history of alcohol or substance abuse
  15. Administration of bile acids or lipid binding resins, or phenylbutyrates during the screening period
  16. Criterion has been deleted as of Amendment 3
  17. Administration of any drug, biologic, or medical device during the screening period
  18. Previous use of an ileal bile acid transporter inhibitor (IBATi)
  19. History of non-adherence to medical regimens, unreliability, medical condition, mental instability or cognitive impairment that, in the opinion of the Investigator or Sponsor medical monitor, could compromise the validity of , compromise the safety of the subject, or lead to nonadherence with the study protocol or inability to conduct the study procedures
  20. Known to maralixibat or any of its .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Maralixibat

    Participants will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) orally twice daily for 26 weeks.

    Drug: Maralixibat

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.

    Other: Placebo

Interventions

  • Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.

    Also known as: Formerly LUM001 and SHP625

  • OtherPlacebo

    Placebo matching to maralixibat orally twice daily for 26 weeks.

06

What researchers measure

Primary outcomes

  1. Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort

    The primary efficacy endpoint is the mean change in the average morning ItchRO(Obs) severity score between baseline and Weeks 15-26, using 4-week average morning ItchRO(Obs) severity scores (Mixed Model Repeated Measures). The baseline average morning ItchRO(Obs) severity score is defined as the 4-week average morning ItchRO(Obs) severity score prior to the first dose of the study medication. ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.

    Time frame: MMRM model was used with inputs of the average changes from baseline (BL) to Weeks 1-6, 7-10, 11-14, 15-18, 19-22, 23-26, and other covariates. The average change from BL over Weeks 15-26 is calculated in the model and presented as a single number.

Secondary outcomes

  1. Mean Change in Total sBA Level in the Primary Cohort.

    Mean change in total sBA level between baseline and average of Weeks 18, 22 and 26.

    Time frame: Baseline and average of Weeks 18, 22 and 26

  2. Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6)

    Mean change in the average morning ItchRO(Obs) severity score between baseline and Week 15 through Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.

    Time frame: Between Baseline and Week 15 through Week 26

  3. Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

    Mean change in total sBA level between baseline and average of Weeks 18, 22, and 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

    Time frame: Between Baseline and average of Weeks 18, 22 and 26

  4. Proportion of ItchRO(Obs) Responders in the Primary Cohort

    Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC2 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 or an average severity score of ≤1.0.

    Time frame: Week 15 to Week 26 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26)

  5. Proportion of sBA Responders in the Primary Cohort

    Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC2, using the average value from Weeks 18, 22 and 26 values. The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), OR a ≤-75% average percent change from baseline.

    Time frame: Average value from Weeks 18, 22 and 26

  6. Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

    Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 OR an average severity score of ≤1.0.

    Time frame: From Week 15 to Week 26

  7. Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

    Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), or a ≤-75% average percent change from baseline.

    Time frame: Week 18 to Week 26

07

Results

Posted Dec 11, 2023

Participant flow

A total of 93 participants were enrolled at 29 sites in 16 countries (Argentina, Austria, Belgium, Brazil, Canada, Colombia, France, Germany, Italy, Lebanon, Mexico, Poland, Singapore, Turkey, United Kingdom, and United States).

Participant flow — Overall Study
MilestoneMaralixibatPlacebo
Started4746
Dosed 150 ug/kg bid470
Dosed 300 ug/kg bid460
Dosed 450 ug/kg bid450
Dosed 600 ug/kg bid450
Completed4442
Not completed34

Outcome measures

PrimaryMean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort

The primary efficacy endpoint is the mean change in the average morning ItchRO(Obs) severity score between baseline and Weeks 15-26, using 4-week average morning ItchRO(Obs) severity scores (Mixed Model Repeated Measures). The baseline average morning ItchRO(Obs) severity score is defined as the 4-week average morning ItchRO(Obs) severity score prior to the first dose of the study medication. ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.

Time frame:
MMRM model was used with inputs of the average changes from baseline (BL) to Weeks 1-6, 7-10, 11-14, 15-18, 19-22, 23-26, and other covariates. The average change from BL over Weeks 15-26 is calculated in the model and presented as a single number.
Reported as:
Least squares mean · Score on a scale
Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort
Score on a scalePrimary Cohort MaralixibatPrimary Cohort Placebo
Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort-1.718 (-2.272 to -1.163)-0.628 (-1.136 to -0.121)
Statistical analysis
  • Primary Cohort Maralixibat vs Primary Cohort Placebo · Mixed Models Analysis · p = = 0.0063 · Least-square mean: -1.089 · 95% CI -1.845 to -0.334
SecondaryMean Change in Total sBA Level in the Primary Cohort.

Mean change in total sBA level between baseline and average of Weeks 18, 22 and 26.

Time frame:
Baseline and average of Weeks 18, 22 and 26
Reported as:
Least squares mean · μmol/L
Mean Change in Total sBA Level in the Primary Cohort.
μmol/LPrimary Cohort MaralixibatPrimary Cohort Placebo
Mean Change in Total sBA Level in the Primary Cohort.-175.536 (-256.716 to -94.356)11.187 (-58.073 to 80.446)
Statistical analysis
  • Primary Cohort Maralixibat vs Primary Cohort Placebo · Mixed Models Analysis · p = = 0.0013 · Least-square mean: -186.723 · 95% CI -293.454 to -79.992
SecondaryMean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6)

Mean change in the average morning ItchRO(Obs) severity score between baseline and Week 15 through Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). ItchRo(Obs) Severity Score = Itch Reported Outcome Observer assessment severity score; scale between 0 (not itchy at all) and 4 (extremely itchy); the lower the score the better.

Time frame:
Between Baseline and Week 15 through Week 26
Reported as:
Least squares mean · score on a scale
Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6)
score on a scalePFIC Cohort MaralixibatPFIC Cohort Placebo
Mean Change in the Average Morning ItchRO(Obs) Severity Score in Participants With PFIC (PFIC1, Nt-PFIC2, PFIC3, PFIC4 and PFIC6)-1.811 (-2.178 to -1.444)-0.610 (-1.000 to -0.221)
Statistical analysis
  • PFIC Cohort Maralixibat vs PFIC Cohort Placebo · Mixed Models Analysis · p = < 0.0001 · Least-square mean: -1.200 · 95% CI -1.727 to -0.674
SecondaryMean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

Mean change in total sBA level between baseline and average of Weeks 18, 22, and 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

Time frame:
Between Baseline and average of Weeks 18, 22 and 26
Reported as:
Least squares mean · μmol/L
Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
μmol/LPFIC Cohort MaralixibatPFIC Cohort Placebo
Mean Change in Total sBA Level in Participants With PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)-157.489 (-200.276 to -114.703)2.913 (-42.320 to 48.146)
Statistical analysis
  • PFIC Cohort Maralixibat vs PFIC Cohort Placebo · Mixed Models Analysis · p = < 0.0001 · Least-square mean: -160.403 · 95% CI -220.836 to -99.970
SecondaryProportion of ItchRO(Obs) Responders in the Primary Cohort

Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC2 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 or an average severity score of ≤1.0.

Time frame:
Week 15 to Week 26 using the average value from the three 4-week periods (Weeks 15-18, 19-22 and 23-26)
Reported as:
Number · Number of responders
Proportion of ItchRO(Obs) Responders in the Primary Cohort
Number of respondersPrimary Cohort MaralixibatPrimary Cohort Placebo
Proportion of ItchRO(Obs) Responders in the Primary Cohort84
Statistical analysis
  • Primary Cohort Maralixibat vs Primary Cohort Placebo · Bernard's exact test · p = = 0.0736
SecondaryProportion of sBA Responders in the Primary Cohort

Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC2, using the average value from Weeks 18, 22 and 26 values. The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), OR a ≤-75% average percent change from baseline.

Time frame:
Average value from Weeks 18, 22 and 26
Reported as:
Number · Number of responders
Proportion of sBA Responders in the Primary Cohort
Number of respondersPrimary Cohort MaralixibatPrimary Cohort Placebo
Proportion of sBA Responders in the Primary Cohort51
Statistical analysis
  • Primary Cohort Maralixibat vs Primary Cohort Placebo · Bernard's exact test · p = = 0.0410
SecondaryProportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

Proportion of ItchRO(Obs) responders from Week 15 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. ItchRO responders are defined as a subject having a 4-week average morning ItchRO(Obs) severity change from baseline of ≤-1.0 OR an average severity score of ≤1.0.

Time frame:
From Week 15 to Week 26
Reported as:
Number · Number of responders
Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
Number of respondersPFIC Cohort MaralixibatPFIC Cohort Placebo
Proportion of ItchRO(Obs) Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)218
Statistical analysis
  • PFIC Cohort Maralixibat vs PFIC Cohort Placebo · Bernard's exact test · p = = 0.0023
SecondaryProportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)

Proportion of sBA responders from Week 18 to Week 26 in participants with PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6). The number in the Subject Analysis Set refers to the number of responders. sBA responders are defined as a subject having an average sBA level of \<102 umol/L (applies only if baseline sBA level was ≥102 umol/L), or a ≤-75% average percent change from baseline.

Time frame:
Week 18 to Week 26
Reported as:
Number · Number of responders
Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)
Number of respondersPFIC Cohort MaralixibatPFIC Cohort Placebo
Proportion of sBA Responders PFIC (PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6)152
Statistical analysis
  • PFIC Cohort Maralixibat vs PFIC Cohort Placebo · Bernard's exact test · p = = 0.0004

Adverse events

Collected over Baseline to end of treatment (EOT); where EOT can be up to 26 weeks if participant did not early terminate.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maralixibat0/47 (0%)5/47 (10.6%)47/47 (100%)
Placebo0/46 (0%)3/46 (6.5%)43/46 (93.5%)
Most frequent serious events
Most frequent serious events
EventMaralixibatPlacebo
Urinary tract infectionInfections and infestations2/470/46
Accidental exposure to productInjury, poisoning and procedural complications0/471/46
CoagulopathyBlood and lymphatic system disorders0/471/46
Gastroenteritis viralInfections and infestations0/471/46
SeizureNervous system disorders0/471/46
Vitamin K deficiencyMetabolism and nutrition disorders0/471/46
Blood bilirubin increasedInvestigations1/470/46
CholestasisHepatobiliary disorders1/470/46
ConstipationGastrointestinal disorders1/470/46
Idiopathic pneumonia syndromeRespiratory, thoracic and mediastinal disorders1/470/46
Most frequent other events
Showing 10 of 22
Most frequent other events
EventMaralixibatPlacebo
DiarrhoeaGastrointestinal disorders27/479/46
PyrexiaGeneral disorders17/4713/46
Abdominal painGastrointestinal disorders10/473/46
PruritusSkin and subcutaneous tissue disorders5/478/46
RhinorrhoeaRespiratory, thoracic and mediastinal disorders8/475/46
Blood bilirubin increasedInvestigations7/474/46
CoughRespiratory, thoracic and mediastinal disorders7/475/46
Upper respiratory tract infectionInfections and infestations3/476/46
Alanine aminotransferase increasedInvestigations6/473/46
InfluenzaInfections and infestations6/472/46

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MaralixibatPlaceboTotal
All subjects — <=18 years474693
All subjects — Between 18 and 65 years000
All subjects — >=65 years000
Primary Cohort — <=18 years141731
Primary Cohort — Between 18 and 65 years000
Primary Cohort — >=65 years000
PFIC cohort — <=18 years333164
PFIC cohort — Between 18 and 65 years000
PFIC cohort — >=65 years000
Age, Continuous
Age, Continuous(years)MaralixibatPlaceboTotal
All subjects4.8 ± 4.154.7 ± 3.574.7 ± 3.85
Primary Cohort6.3 ± 5.244.2 ± 3.565.1 ± 4.45
PFIC Cohort4.9 ± 4.104.4 ± 3.614.6 ± 3.85
Sex: Female, Male
Sex: Female, Male(Participants)MaralixibatPlaceboTotal
All subjects — Female272451
All subjects — Male202242
Primary Cohort — Female71118
Primary Cohort — Male7613
PFIC Cohort — Female161834
PFIC Cohort — Male171330
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MaralixibatPlaceboTotal
All subjects — Hispanic or Latino181735
All subjects — Not Hispanic or Latino282755
All subjects — Unknown or Not Reported123
Primary Cohort — Hispanic or Latino9716
Primary Cohort — Not Hispanic or Latino5914
Primary Cohort — Unknown or Not Reported011
PFIC Cohort — Hispanic or Latino161329
PFIC Cohort — Not Hispanic or Latino171633
PFIC Cohort — Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MaralixibatPlaceboTotal
All subjects — American Indian or Alaska Native347
All subjects — Asian303
All subjects — Native Hawaiian or Other Pacific Islander000
All subjects — Black or African American123
All subjects — White363470
All subjects — More than one race347
All subjects — Unknown or Not Reported123
Primary Cohort — American Indian or Alaska Native336
Primary Cohort — Asian000
Primary Cohort — Native Hawaiian or Other Pacific Islander000
Primary Cohort — Black or African American123
Primary Cohort — White9918
Primary Cohort — More than one race123
Primary Cohort — Unknown or Not Reported011
PFIC Cohort — American Indian or Alaska Native347
PFIC Cohort — Asian303
PFIC Cohort — Native Hawaiian or Other Pacific Islander000
PFIC Cohort — Black or African American123
PFIC Cohort — White241943
PFIC Cohort — More than one race246
PFIC Cohort — Unknown or Not Reported022
Region of Enrollment
Region of Enrollment(participants)MaralixibatPlaceboTotal
Argentina213
Austria112
Belgium303
Brazil7310
Canada112
Colombia246
France123
Germany112
Italy246
Lebanon6814
Mexico358
Poland426
Singapore202
Turkey112
United Kingdom202
United States91322
08

Study locations

31 sites
  • Children's Hospital Los Angeles CHLA
    Los Angeles, California 90027, United States
  • Medstar Georgetown University Hospital
    Washington, District of Columbia 20007-2113, United States
  • Advent Health
    Orlando, Florida 32803, United States
  • The Children's Hospital at Montefiore Yeshiva University - Montefiore Medical Center
    New York, New York 10461, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic - Pediatric Institute
    Cleveland, Ohio 44195, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas - UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Texas, Health Science Center San Antonio
    San Antonio, Texas 78229, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hospital Italiano de Buenos Aires
    Buenos Aires, Argentina
  • Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde
    Wien, Austria
  • Universite Catholique de Louvain (UCLouvain) - Cliniques Universitaires Saint-Luc
    Bruxelles, Belgium
  • Sociedade Beneficente de Senhoras Hospital Sírio-Libanês
    São Paulo, Brazil
  • University of Alberta - Women and Children's Health Research Institute
    Edmonton, Canada
  • Fundacion Cardioinfantil - Departamento de Investigaciones
    Bogotá, Colombia
  • Hospices Civils de Lyon - Hopital Femme Mere Enfant Service de Gastroenterologie, Hepatologie et Nutrition
    Lyon, France
  • CHU de Marseille, Hôpital de la Timone
    Marseille, France
  • CHU de Toulouse - Hôpital des Enfants
    Toulouse, 31059, France
  • Medizinische Hochschule Hannover
    Hanover, Germany
  • Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK)
    Budapest, 1083, Hungary
  • Hospital Papa Giovanni XXIII / Unità di Pediatria
    Bergamo, Italy
  • Ospedale Pediatrico Bambino Gesu
    Roma, Italy
  • Hotel Dieu de France
    Beirut, Lebanon
  • Consultario de Joshue David Covarrubias Esquer
    Zapopan, Mexico
  • Instytut Pomnik Centrum Zdrowia Dziecka
    Warsaw, Poland
  • KK Women's and Children's Hospital
    Singapore, Singapore
  • Koc University Hospital
    Istanbul, Turkey
  • Birmingham Children's Hospital
    Birmingham, United Kingdom
  • King's College Hospital NHS
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Sep 2022, 37 months.

Results were first posted in Dec 2023, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2019
First posted
Apr 5, 2019
StartActual
Jul 9, 2019
Primary completionActual
Sep 1, 2022
CompletionActual
Sep 1, 2022
Results first posted
Dec 11, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03905330
Responsible party
Sponsor
First posted
Apr 5, 2019
Start date
Jul 9, 2019
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022
Results posted
Dec 11, 2023
Last update
Dec 11, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion